Cabaletta Bio, Inc. Logo

Cabaletta Bio, Inc.

Develops engineered T cell therapies for B cell-mediated autoimmune diseases.

CABA | US

Overview

Corporate Details

ISIN(s):
US12674W1099
LEI:
Country:
United States of America
Address:
2929 ARCH STREET, 19104 PHILADELPHIA

Description

Cabaletta Bio, Inc. is a clinical-stage biotechnology company focused on developing engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company utilizes its Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) platform to develop treatments that aim to provide deep, durable, and potentially curative responses. Its lead product candidate, rese-cel, is a fully human CD19-CAR T cell therapy designed to transiently eliminate B cells, thereby enabling an "immune system reset." Rese-cel is being advanced in Phase 1/2 clinical trials for a range of autoimmune diseases, including systemic lupus erythematosus, myositis, systemic sclerosis, and generalized myasthenia gravis.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Select rows to enable
Date Filing Language Type / Size Actions
2024-12-15
English
4.2 MB
2024-10-30
German
1.8 MB
2024-08-14
French
0.5 MB
2024-05-22
English
2.1 MB
2024-03-10
English
3.5 MB
2024-01-15
German
1.2 MB
2023-11-20
English
5.1 MB

Full Filing History Restricted

Access to specific historical documents or filtered results is limited in the Web UI. Request access to the complete dataset.

Automate Your Workflow. Get a real-time feed of all Cabaletta Bio, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Cabaletta Bio, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Cabaletta Bio, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Adaptive Biotechnologies Corp Logo
Decodes the adaptive immune system to develop products for diagnosing and treating disease.
United States of America
ADPT
Adeia Inc. Logo
R&D company that licenses IP for the media, entertainment, and semiconductor industries.
United States of America
ADEA
Aditxt, Inc. Logo
Acquires, develops, and deploys health technologies to address major health challenges.
United States of America
ADTX
Advanced Biomed Inc. Logo
Develops microfluidic biochip diagnostic systems for precision oncology.
United States of America
ADVB
AIM ImmunoTech Inc. Logo
Immuno-pharma company developing therapeutics for oncology, immune, and viral diseases.
United States of America
AIM
Ainos, Inc. Logo
Develops AI-driven diagnostics, immune therapeutics, and telehealth POCT devices.
United States of America
AIMD
Akero Therapeutics, Inc. Logo
Clinical-stage company developing treatments for serious metabolic diseases like MASH.
United States of America
AKRO
Aladdin Healthcare Technologies SE Logo
Develops AI-powered tools for drug discovery and diagnostics for age-related conditions.
Germany
NMI
Alaunos Therapeutics, Inc. Logo
Clinical-stage immuno-oncology company developing TCR-T cell therapies for solid tumors.
United States of America
TCRT
Aligos Therapeutics, Inc. Logo
A clinical-stage biopharmaceutical company developing therapeutics for liver and viral diseases.
United States of America
ALGS

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.